Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Clin Cancer Res. 2014 Sep 1;20(17):4499–4510. doi: 10.1158/1078-0432.CCR-14-0348

Figure 1. LCS6-variant patients have improved PFS vs non-variant patients in response to EGFR moAbs monotherapy for all patients, with no benefit of additional chemotherapy.

Figure 1

(A) Median progression-free survival (PFS) by KRAS LCS6 genotype in all patients treated with anti-EGFR moAbs monotherapy as salvage treatment. (B) Median PFS according to the KRAS 3′-UTR LCS6 SNP genotype status in all patients treated with anti-EGFR moAbs based combination chemotherapy as salvage treatment. (C) Median PFS according to type of therapy in all KRAS 3′-UTR LCS6 SNP carriers. (D) Median PFS according to type of therapy in all non-KRAS 3′-UTR LCS6 SNP carriers.